✦ LIBER ✦

Clonal structure of tumors: Interclonal variation in secretion of growth factors and cellular response to them

✍ Scribed by A. A. Stavrovskaya; V. B. Kishkina; T. P. Stromskaya

Publisher: Springer US
Year: 1986
Tongue: English
Weight: 265 KB
Volume: 102
Category: Article
ISSN: 0007-4888
DOI: 10.1007/bf00836217

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The response to epidermal growth factor

The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, invasion and expression of proteinase inhibitors

✍ H. Mizoguchi; S. Komiyama; K. Matsui; R. Hamanaka; M. Ono; A. Kiue; M. Kobayash; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 762 KB

Three cancer cell lines, IMC-2, IMC-3 and IMC-4, were established from a single tumor of a patient with maxillary cancer. We examined responses to epidermal growth factor (EGF) of these 3 cell lines with regard to cell growth and tumor invasion. The growth rate of IMC-2 in nude mice was markedly fas

Functional and structural properties of

Functional and structural properties of stannin: Roles in cellular growth, selective toxicity, and mitochondrial responses to injury

✍ M.L. Billingsley; J. Yun; B.E. Reese; C.E. Davidson; B.A. Buck-Koehntop; G. Vegl 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract Stannin (Snn) was discovered using subtractive hybridization methodology designed to find gene products related to selective organotin toxicity and apoptosis. The cDNAs for Snn were first isolated from brain tissues sensitive to trimethyltin, and were subsequently used to localize, char

Response to dual blockade of epidermal g

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2